Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6468MR)

This product GTTS-WQ6468MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6468MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12118MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ12892MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ10795MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ2581MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ15248MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ14579MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ3278MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ604MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW